Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Maternal BMI, Peripheral Deiodinase Activity, and Plasma Glucose: Relationships Between White Women in the HAPO Study.

Haddow JE, Metzger BE, Lambert-Messerlian G, Eklund E, Coustan D, Catalano P, Palomaki GE.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2593-2600. doi: 10.1210/jc.2018-02328.

PMID:
30753726
2.

Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing.

Palomaki GE, Kloza EM.

Genet Med. 2018 Nov;20(11):1312-1323. doi: 10.1038/gim.2018.22. Epub 2018 Apr 26.

PMID:
30514979
3.

Fewer women aged 35 and older choose serum screening for Down's syndrome: Impact and implications.

Lambert-Messerlian G, Palomaki GE.

J Med Screen. 2019 Jun;26(2):59-66. doi: 10.1177/0969141318797961. Epub 2018 Sep 25.

PMID:
30253677
4.

Updates on Screening, Prevention, Treatment, and Genetic Markers for Preeclampsia.

Palomaki GE, Martin JN Jr, Karumanchi SA, Poon LC.

Clin Chem. 2018 Dec;64(12):1684-1689. doi: 10.1373/clinchem.2018.289801. Epub 2018 Sep 10. No abstract available.

PMID:
30201802
5.

Peripheral deiodinase activity: A potential explanation for the association between maternal weight and gestational hyperglycemia.

Haddow JE, Lambert-Messerlian G, Eklund E, Neveux LM, Palomaki GE.

Obstet Med. 2018 Jun;11(2):73-78. doi: 10.1177/1753495X17733223. Epub 2017 Oct 12.

6.

Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia.

Rehfeldt M, Eklund E, Struck J, Sparwasser A, O'Brien B, Palomaki GE, Köhrle J, Bergmann A, Lambert-Messerlian G.

Pregnancy Hypertens. 2018 Jan;11:124-128. doi: 10.1016/j.preghy.2017.11.001. Epub 2017 Nov 7.

PMID:
29133069
7.

Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy.

Haddow JE, Palomaki GE.

N Engl J Med. 2017 Aug 17;377(7):700-1. doi: 10.1056/NEJMc1707415. No abstract available.

PMID:
28816427
8.

Measuring maternal serum screening markers for Down's syndrome in plasma collected for cell-free DNA testing.

Lambert-Messerlian GM, Eklund EE, Neveux LM, Palomaki GE.

J Med Screen. 2017 Sep;24(3):113-119. doi: 10.1177/0969141316670193. Epub 2016 Oct 21.

PMID:
28756761
9.

CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance.

Oglesbee D, Cowan TM, Pasquali M, Wood TC, Weck KE, Long T, Palomaki GE.

Genet Med. 2018 Jan;20(1):83-90. doi: 10.1038/gim.2017.61. Epub 2017 Jun 29.

10.

Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

Bradley LA, Haddow HRM, Palomaki GE.

Genet Med. 2017 Nov;19(11):1187-1201. doi: 10.1038/gim.2017.30. Epub 2017 May 18. Review.

PMID:
28640238
11.

Emerging Considerations for Noninvasive Prenatal Testing.

Korpi-Steiner N, Chiu RWK, Chandrasekharan S, Chitty LS, Evans MI, Jackson JA, Palomaki GE.

Clin Chem. 2017 May;63(5):946-953. doi: 10.1373/clinchem.2016.266544. Epub 2017 Mar 15. No abstract available.

12.

Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA.

O'Brien BM, Halliday J, Lambert-Messerlian G, Eklund EE, Kloza E, Palomaki GE.

Prenat Diagn. 2017 Mar;37(3):303-305. doi: 10.1002/pd.5010. Epub 2017 Feb 17. No abstract available.

PMID:
28124379
13.

Serum Progesterone Levels in Pregnant Women with Obstructive Sleep Apnea: A Case Control Study.

Lee J, Eklund EE, Lambert-Messerlian G, Palomaki GE, Butterfield K, Curran P, Bourjeily G.

J Womens Health (Larchmt). 2017 Mar;26(3):259-265. doi: 10.1089/jwh.2016.5917. Epub 2017 Jan 19.

14.

The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population.

Palomaki GE, Kloza EM, O'Brien BM, Eklund EE, Lambert-Messerlian GM.

Genet Med. 2017 Jul;19(7):778-786. doi: 10.1038/gim.2016.194. Epub 2017 Jan 12.

15.

Where have all the trisomies gone?

Palomaki GE, Lambert-Messerlian GM, Haddow JE.

Am J Obstet Gynecol. 2016 Nov;215(5):583-587.e1. doi: 10.1016/j.ajog.2016.06.046.

PMID:
27793310
16.

Confusion between analytic validity and clinical validity.

Palomaki GE, Haddow JE.

Am J Obstet Gynecol. 2016 Oct;215(4):533-4. doi: 10.1016/j.ajog.2016.06.008. Epub 2016 Jun 15. No abstract available.

PMID:
27316786
17.

Results from an external proficiency testing program: 11 years of molecular genetics testing for myotonic dystrophy type 1.

Richards CS, Palomaki GE, Hegde M.

Genet Med. 2016 Dec;18(12):1290-1294. doi: 10.1038/gim.2016.59. Epub 2016 Jun 2.

PMID:
27253733
18.

Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes.

Haddow JE, Craig WY, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

PLoS One. 2016 Feb 24;11(2):e0149065. doi: 10.1371/journal.pone.0149065. eCollection 2016.

19.

Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population.

Maredia H, Lambert-Messerlian GM, Palomaki GE, Viali S, Hawley NL, McGarvey ST.

Clin Biochem. 2016 Jul;49(10-11):782-6. doi: 10.1016/j.clinbiochem.2016.02.006. Epub 2016 Feb 18.

20.

Prenatal serum screening markers may not require adjustment in former smokers.

Lambert-Messerlian G, Palomaki GE.

Prenat Diagn. 2015 Dec;35(13):1371-3. doi: 10.1002/pd.4695. Epub 2015 Nov 5. No abstract available.

PMID:
26413989
21.

Use of first or second trimester serum markers, or both, to predict preeclampsia.

Lambert-Messerlian G, Eklund EE, Chien EK, Rosene-Montella K, Neveux LM, Haddow HR, Palomaki GE.

Pregnancy Hypertens. 2014 Oct;4(4):271-8. doi: 10.1016/j.preghy.2014.07.001. Epub 2014 Jul 29.

PMID:
26104816
22.

An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism.

Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME.

Thyroid. 2015 Aug;25(8):949-53. doi: 10.1089/thy.2015.0085. Epub 2015 Jun 23.

23.

The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates.

Grosse SD, Palomaki GE, Mvundura M, Hampel H.

Genet Med. 2015 Jun;17(6):510-1. doi: 10.1038/gim.2015.53. No abstract available.

24.
25.

Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage.

Palomaki GE.

J Med Screen. 2015 Sep;22(3):109-11. doi: 10.1177/0969141315579701. Epub 2015 May 5. No abstract available.

PMID:
25943835
26.

Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?

Palomaki GE, Ashwood ER, Best RG, Lambert-Messerlian G, Knight GJ.

Genet Med. 2015 Nov;17(11):897-900. doi: 10.1038/gim.2015.39. Epub 2015 Apr 2.

PMID:
25834952
27.

Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia.

Palomaki GE, Haddow JE, Haddow HR, Salahuddin S, Geahchan C, Cerdeira AS, Verlohren S, Perschel FH, Horowitz G, Thadhani R, Karumanchi SA, Rana S.

Prenat Diagn. 2015 Apr;35(4):386-93. doi: 10.1002/pd.4554. Epub 2015 Feb 4.

28.

A flawed challenge but valid recommendation: a response to Takoudes and Hamar.

Palomaki GE, Ashwood ER, Weck KE.

Ultrasound Obstet Gynecol. 2015 Jan;45(1):117. doi: 10.1002/uog.14739. No abstract available.

29.

Circulating cell free DNA testing: are some test failures informative?

Palomaki GE, Kloza EM, Lambert-Messerlian GM, van den Boom D, Ehrich M, Deciu C, Bombard AT, Haddow JE.

Prenat Diagn. 2015 Mar;35(3):289-93. doi: 10.1002/pd.4541. Epub 2015 Jan 8.

PMID:
25449554
30.

Next generation sequencing in clinical diagnostics: experiences of early adopters.

Lyon E, Cockerill FR 3rd, Bale SJ, Beadling C, Bry L, Hagenkord J, Kulkarni S, Press R, Palomaki GE.

Clin Chem. 2015 Jan;61(1):41-9. doi: 10.1373/clinchem.2014.222687. Epub 2014 Nov 24. No abstract available.

31.

Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics.

Palomaki GE.

Genet Med. 2015 Jan;17(1):24-6. doi: 10.1038/gim.2014.167. Epub 2014 Nov 6. No abstract available.

PMID:
25375653
32.

Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy.

Kloza EM, Haddow PK, Halliday JV, O'Brien BM, Lambert-Messerlian GM, Palomaki GE.

J Genet Couns. 2015 Apr;24(2):259-66. doi: 10.1007/s10897-014-9758-8. Epub 2014 Sep 10.

PMID:
25204423
33.

Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center.

O'Brien BM, Kloza EM, Halliday JV, Lambert-Messerlian GM, Palomaki GE.

Genet Test Mol Biomarkers. 2014 Oct;18(10):665-9. doi: 10.1089/gtmb.2014.0125. Epub 2014 Aug 19.

PMID:
25137409
34.

Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys.

Lyon E, Schrijver I, Weck KE, Ferreira-Gonzalez A, Richards CS, Palomaki GE; CAP/ACMG Biochemical and Molecular Genetics Committee.

Genet Med. 2015 Mar;17(3):219-25. doi: 10.1038/gim.2014.93. Epub 2014 Jul 31.

PMID:
25077647
35.

Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.

Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.

Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.

PMID:
24946157
36.

Implications of High Free Thyroxine (FT4) concentrations in euthyroid pregnancies: the FaSTER trial.

Haddow JE, Craig WY, Neveux LM, Haddow HR, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

J Clin Endocrinol Metab. 2014 Jun;99(6):2038-44. doi: 10.1210/jc.2014-1053. Epub 2014 Feb 28.

37.

Results of the College of American Pathology/American College of Medical Genetics and Genomics external proficiency testing from 2006 to 2013 for three conditions prevalent in the Ashkenazi Jewish population.

Feldman GL, Schrijver I, Lyon E, Palomaki GE; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.

Genet Med. 2014 Sep;16(9):695-702. doi: 10.1038/gim.2014.14. Epub 2014 Feb 27.

PMID:
24577267
38.

Comparison of radiographic femur measurements in stillbirths and neonatal deaths to ultrasound measurements in ongoing pregnancies.

Pinar H, Palomaki GE, Haddow HR, Rowles A, Torabi R.

Pediatr Dev Pathol. 2014 Mar-Apr;17(2):107-11. doi: 10.2350/14-01-1435-OA.1. Epub 2014 Feb 27.

PMID:
24575801
39.

Down syndrome screening: suitability of a WHO 5 standardized total hCG assay.

Palomaki GE, Lambert-Messerlian G.

Clin Biochem. 2014 May;47(7-8):629-31. doi: 10.1016/j.clinbiochem.2014.01.013. Epub 2014 Jan 23.

PMID:
24462966
40.

A new era in noninvasive prenatal testing.

Ashwood ER, Palomaki GE.

N Engl J Med. 2013 Nov 28;369(22):2164. doi: 10.1056/NEJMc1311604. No abstract available.

PMID:
24283243
41.

Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies.

Lambert-Messerlian G, Kloza EM, Williams J 3rd, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, De Biasio P, Borrell A, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE.

Genet Med. 2014 May;16(5):419-22. doi: 10.1038/gim.2013.149. Epub 2013 Oct 3.

PMID:
24091801
42.

Screening for down syndrome in the United States: results of surveys in 2011 and 2012.

Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE.

Arch Pathol Lab Med. 2013 Jul;137(7):921-6. doi: 10.5858/arpa.2012-0319-CP.

PMID:
23808464
43.

Three-year experience of a CAP/ACMG methods-based external proficiency testing program for laboratories offering DNA sequencing for rare inherited disorders.

Richards CS, Palomaki GE, Lacbawan FL, Lyon E, Feldman GL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.

Genet Med. 2014 Jan;16(1):25-32. doi: 10.1038/gim.2013.65. Epub 2013 May 23.

PMID:
23703682
44.

Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma.

Mazloom AR, Džakula Ž, Oeth P, Wang H, Jensen T, Tynan J, McCullough R, Saldivar JS, Ehrich M, van den Boom D, Bombard AT, Maeder M, McLennan G, Meschino W, Palomaki GE, Canick JA, Deciu C.

Prenat Diagn. 2013 Jun;33(6):591-7. doi: 10.1002/pd.4127.

PMID:
23592550
45.

The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies.

Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE.

Prenat Diagn. 2013 Jul;33(7):667-74. doi: 10.1002/pd.4126. Epub 2013 May 31.

PMID:
23592541
46.

Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N.

J Urol. 2013 Aug;190(2):389-98. doi: 10.1016/j.juro.2013.02.005. Epub 2013 Mar 29. Review.

PMID:
23545099
47.

Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review.

Palomaki GE, Melillo S, Marrone M, Douglas MP.

Genet Med. 2013 Aug;15(8):600-11. doi: 10.1038/gim.2013.8. Epub 2013 Mar 14. Review.

48.

High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma.

Jensen TJ, Zwiefelhofer T, Tim RC, Džakula Ž, Kim SK, Mazloom AR, Zhu Z, Tynan J, Lu T, McLennan G, Palomaki GE, Canick JA, Oeth P, Deciu C, van den Boom D, Ehrich M.

PLoS One. 2013;8(3):e57381. doi: 10.1371/journal.pone.0057381. Epub 2013 Mar 6.

49.

Maternal Body Mass Index during Pregnancy and Offspring Neurocognitive Development.

Craig WY, Palomaki GE, Neveux LM, Haddow JE.

Obstet Med. 2013 Mar;6(1):20-25. Epub 2013 Mar 1.

50.

Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening.

Lambert-Messerlian GM, Palomaki GE, Eklund EE, Kloza EM, Neveux LM, Phipps MG, Canick JA.

J Med Screen. 2012 Dec;19(4):164-70. doi: 10.1258/jms.2012.012086. Epub 2012 Dec 31.

PMID:
23277614

Supplemental Content

Loading ...
Support Center